Company intelligence / Profile preview

Oractive Swiss

Muttenz, Basel-Landschaft, Switzerlandoractive.ch ↗

Ownership: Private
Development stage: Other

Overview

Oractive AG was a Swiss biotechnology company focused on the development of innovative oral delivery systems for peptides and proteins. The company's proprietary technology platform aimed to overcome the biological barriers of the gastrointestinal tract, enabling the oral administration of drugs that typically require injection, such as insulin. Based in Muttenz, Oractive was a spin-off from the University of Applied Sciences and Arts Northwestern Switzerland (FHNW). Despite promising early-stage research into oral peptide formulations, the company entered liquidation in 2021.

Therapeutic areas: Endocrinology
Modalities: PeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Oractive Swiss.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oractive Swiss.

Explore the full profile